PDCD1 and neoplasm: Hence, a combination of ECT with anti-CTLA4 or anti-PD1 antibodies could be an elegant way to destroy the initial nodule while raising efficient anti-tumor responses to ultimately eliminate remaining and circulating cancer cells.